Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized AZithromycin/metronidAZole, in Combination With Standard Induction Therapy, to Achieve a Fecal Microbiome Community Structure and Metagenome Changes Associated With Sustained Remission in Pediatric Crohn's Disease (CD): a Pilot Study

NCT04186247 is registered in ClinicalTrials.gov with University of North Carolina, Chapel Hill as lead sponsor.

NCT NCT04186247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04186247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized AZithromycin/metronidAZole, in Combination With Standard Induction Therapy, to Achieve a Fecal Microbiome Community Structure and Metagenome Changes Associated With Sustained Remission in Pediatric Crohn's Disease (CD): a Pilot Study
Lead sponsor
University of North Carolina, Chapel Hill
Phase
Phase 2
Overall status
Terminated
Start date
August 13, 2021
Completion date
December 31, 2023
Enrollment
13 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, pediatric crohns disease